Epstein-Barr Virus-Positive Gastric Carcinoma Has a Distinct Protein Expression Profile in Comparison with Epstein-Barr Virus-Negative Carcinoma

Lee, Hye Seung; Chang, Mee Soo; Yang, Han Kwang; Lee, Byung Lan; Kim, Woo Ho

doi:10.1158/1078-0432.ccr-1122-3

Cited by 110 publications

(88 citation statements)

References 20 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of EBV infection in our gastric AC cases corresponds well with the findings of others, where frequencies between 5% and 14% have been reported. 10,11 On the other hand, we cannot substantiate the results of Corvalan et al,…”

contrasting

confidence: 81%

Esophageal (Barrett's) adenocarcinoma is not associated with Epstein-Barr virus infection: An analysis of 162 cases

et al. 2005

View full text Add to dashboard Cite

contrasting

confidence: 81%

Esophageal (Barrett's) adenocarcinoma is not associated with Epstein-Barr virus infection: An analysis of 162 cases

et al. 2005

View full text Add to dashboard Cite

“…Although previous studies of EBV DNA in gastric tumour tissue and survival have produced inconsistent results (Chang et al, 2001;Lee et al, 2004), some have found improved survival associated with EBV, at least in subgroups (Koriyama et al, 2002;Lee et al, 2004;van Beek et al, 2004). Our association between high EBNA titres and improved survival was also limited to a subgroup, cardia cancers, although this finding may be due to chance.…”

Section: Discussionmentioning

confidence: 56%

Epstein–Barr virus serology and gastric cancer incidence and survival

Koshiol

Qiao

et al. 2007

Br J Cancer

View full text Add to dashboard Cite

Among 185 cases of gastric cancer and 200 controls in Linxian, China, Epstein -Barr virus (EBV) seropositivity was not associated with increased risk of gastric cancer. High EBV nuclear antigen titres were associated with longer survival in cardia cancer cases, possibly due to chance. (Young and Rickinson, 2004), leading to speculation that it may also cause gastric cancer.Previous studies relating EBV to gastric cancer have primarily been tumour-based. The only previous study of prediagnostic EBV serology and gastric cancer incidence (Levine et al, 1995) found generally elevated odds ratios (ORs) for EBV seropositivity and gastric cancer, but included only 46 cases. No previous study has evaluated prediagnostic EBV serology and gastric cancer survival.We prospectively evaluated the associations between baseline EBV serology in relation to (1) subsequent gastric cancer and (2) survival among gastric cancer patients in the Linxian General Population Nutrition Intervention Trial (NIT) cohort in China. MATERIALS AND METHODSThe NIT was a cancer chemoprevention trial in Linxian, China, conducted from March 1986 through May 1991, that enrolled 29 584 participants (Blot et al, 1993). Follow-up for additional survival is available through May 2001 (Tran et al, 2005). We analysed the relation of baseline EBV seropositivity to gastric cancer incidence in a nested case -control study of cardia cancer cases (N ¼ 102, a random sample of the 435 cases that arose during the trial period), non-cardia cancer cases (N ¼ 83), and randomly selected controls (N ¼ 200). Case and control selection methods have been described elsewhere (Mark et al, 2000). We also analysed the association between EBV seropositivity and survival among gastric cancer cases.We tested for IgA antibodies against the EBV viral capsid antigen (VCA IgA) and the diffuse early antigen (EA-D IgA), and for IgG antibodies against the EBV viral capsid antigen (VCA IgG), diffuse early antigen (EA-D IgG), restricted early antigen (EA-R IgG), and EBV nuclear antigen complex (EBNA) using immunofluorescence assays, as previously described (Levine et al, 1995). EA-D IgA was not detectable. EBV VCA IgA, EA-D IgG, and EA-R IgG antibodies were detected in o15% of cases and controls and so were categorised as positive or negative. EBV VCA IgG and EBNA antibodies, which were detectable in all subjects, were classified as high if above the median category of antibody titres in controls and low otherwise. VCA IgG antibody titres were also analysed ordinally.Unconditional logistic regression was used to calculate ORs and 95% confidence intervals (CIs) for prediagnostic EBV serostatus and gastric cancer, controlling for age and gender. Other potential confounders (e.g., smoking, alcohol, Helicobacter pylori) were considered but did not affect the estimate for VCA IgG. KaplanMeier curves and age-and gender-adjusted Cox models were used to evaluate gastric cancer survival by baseline VCA IgG and EBNA. RESULTSCases tended to be older than controls and were more likely to be males, sm...

show abstract

“…In cases where more than 10% of tumor cells are immunoreactive, immunostaining is regarded as positive 27,28 or high labeling index for Ki-67. 29 MUC1, MUC2, MUC5AC, and MUC6 protein expression status is positive when more than 20% of the tumor cells display immunoexpression in the cytoplasm.…”

Section: Immunohistochemistrymentioning

confidence: 99%

Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive factors

et al. 2009

Self Cite

View full text Add to dashboard Cite

Appendiceal mucinous neoplasms have been the focus of considerable debate in recent years. We histologically classified 70 appendiceal mucinous neoplasms into three categories: 32 mucinous adenoma, 23 mucinous neoplasm of uncertain malignant potential, and 15 mucinous adenocarcinomas. Immunohistochemistry was performed for 24 proteins in different functional categories, specifically, oncogenic proteins (bcl-2, b-catenin, CEA, C-erbB2, c-kit, Cox-2, Cyclin D1, EGFR, Ki-67, NF-jB, VEGF), tumor suppressors (E-cadherin, FHIT, hMLH1, p53, p63, smad4), cell-cycle regulators (p21, p27, p16), and mucin proteins (MUC1, MUC2, MUC5AC, MUC6). Our data showed that 9 out of the 24 proteins were more frequently altered in the mucinous adenocarcinoma group than in the mucinous adenoma group (Po0.05), including b-catenin (13% in mucinous adenoma vs 60% in mucinous adenocarcinoma), CyclinD1 (44 vs 87%), Ki-67 (high labeling index: 31 vs 67%), NF-jB (19 vs 60%), VEGF (16 vs 87%), E-cadherin (0 vs 47%), p53 (6 vs 40%), MUC2 (9 vs 67%), and MUC5AC (3 vs 40%). The distinct immunoexpression profile of mucinous neoplasm of uncertain malignant potential was placed between those of mucinous adenoma and mucinous adenocarcinoma (Po0.05). Moreover, the mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma categories displayed differences in terms of the number of altered markers among the nine proteins (Po0.05; mean 1.4 vs 2.6 vs 5.5, respectively). In mucinous adenocarcinoma, the p53 status was related to disease-free survival and overall survival of patients (Po0.05, both). NF-jB status and the number of altered protein markers made statistically marginal impacts on disease-free survival; also b-catenin loss, on overall survival of patients. In conclusion, protein immunoexpression profiles may facilitate the classification of appendiceal mucinous neoplasms. In our study, the three tumor categories of mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma exhibited distinct immunoexpression profiles. Five and more altered protein markers, p53 overexpression, NF-jB positivity, and b-catenin loss were predictive factors of adverse clinical outcomes in appendiceal mucinous adenocarcinomas.

show abstract

Epstein-Barr Virus-Positive Gastric Carcinoma Has a Distinct Protein Expression Profile in Comparison with Epstein-Barr Virus-Negative Carcinoma

Cited by 110 publications

References 20 publications

Esophageal (Barrett's) adenocarcinoma is not associated with Epstein-Barr virus infection: An analysis of 162 cases

Esophageal (Barrett's) adenocarcinoma is not associated with Epstein-Barr virus infection: An analysis of 162 cases

Epstein–Barr virus serology and gastric cancer incidence and survival

Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive factors

Contact Info

Product

Resources

About